Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,037 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dietary sodium Clear all
Not listed Phase 2 Interventional Results available

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

NCT00492778
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Cancer
Interventions
3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy
Radiation · Drug
Lead sponsor
GOG Foundation
Network
Eligibility
Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
439
States / cities
Auburn, California • Berkeley, California • Burbank, California + 292 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 15, 2026, 1:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural and Psychological Mechanisms of Pain Perception

NCT02446262
View directory record Official record
Conditions
Pain, Normal Physiology, Healthy Volunteers
Interventions
Instructions, Attention, Thermal Pain, Placebo instructions
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension

NCT03390426
View directory record Official record
Conditions
Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion
Interventions
Mepivacaine, Perifemoral Injection of Local Anesthetic, Saline
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 15, 2026, 1:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Melatonin and Salt on Blood Vessel Function

NCT04325191
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Melatonin, Placebo
Dietary Supplement · Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

NCT02535325
View directory record Official record
Conditions
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7, Stage III Lung Large Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Adenocarcinoma AJCC v7, Stage IIIA Lung Large Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Adenocarcinoma AJCC v7, Stage IIIB Lung Large Cell Carcinoma AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Adenocarcinoma AJCC v7, Stage IV Lung Large Cell Carcinoma AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy, Methoxyamine, Methoxyamine Hydrochloride, Pemetrexed, Pemetrexed Disodium
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 15, 2026, 1:55 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240
View directory record Official record
Conditions
Alopecia Areata
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 63 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
78
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

NCT02828358
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Azacitidine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Hydrocortisone Sodium Succinate, Leucovorin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Thioguanine, Vincristine, Vincristine Sulfate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 364 Days
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 128 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 15, 2026, 1:55 PM EDT
Terminated Not applicable Interventional

Reducing Insulin, Growth Hormones, and Tumors

NCT03785808
View directory record Official record
Conditions
Diet Modification, Lung Cancer
Interventions
Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control)
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Accuracy of Current Techniques in Quantifying Ketone Levels

NCT06909331
View directory record Official record
Conditions
Placebo - Control, Exogenous Ketone Salt
Interventions
Exogenous ketone salt, Placebo drink solution
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00096512
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Idiopathic Intracranial Hypertension Treatment Trial

NCT01003639
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Placebo, Formal weight loss counselling program
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 15, 2026, 1:55 PM EDT
Not listed Phase 1 Interventional

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

NCT03129139
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions
Minnelide™Capsules
Drug
Lead sponsor
Minneamrita Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 15, 2026, 1:55 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Gut Microbiome, Metabolome, and SSBP

NCT07790900
View directory record Official record
Conditions
Salt-sensitivity of Blood Pressure
Interventions
Dietary sodium
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

NCT07118592
View directory record Official record
Conditions
Hypertension (HTN), Cardiometabolic Diseases
Interventions
Low Salt Diet, High Salt Diet, Saline Infusion
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Recruiting Phase 2Phase 3 Interventional

MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder

NCT07118839
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions
Full Dose MDMA, MDMA-Assisted psychotherapy, Active Placebo Dose MDMA
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
West Haven, Connecticut • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Terminated Phase 2 Interventional Results available

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

NCT00945477
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
Illinois CancerCare, P.C.
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Bloomington, Illinois • Ottawa, Illinois • Pekin, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone

NCT04079010
View directory record Official record
Conditions
Blood Flow Restriction, Growth Hormone, Strength Outcomes, Arginine
Interventions
BFR, Arginine, Placebo Pill
Procedure · Dietary Supplement
Lead sponsor
University of Mary Hardin-Baylor
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Belton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

NCT02730546
View directory record Official record
Conditions
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7
Interventions
Carboplatin, Computed Tomography, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Pembrolizumab, Positron Emission Tomography, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Procedure · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Salt in Postural Tachycardia Syndrome

NCT01547117
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
Blood Volume, Total Blood Volume, Exercise Capacity Test - Bicycle, Posture Study
Radiation · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

NCT00359190
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
8
States / cities
Miami, Florida • Durham, North Carolina • Allentown, Pennsylvania + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer

NCT03117920
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Minnelide
Drug
Lead sponsor
Minneamrita Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

NCT00025259
View directory record Official record
Conditions
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Involved-Field Radiation Therapy, Prednisone, Vincristine Sulfate Liposome
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
1,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
153
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 15, 2026, 1:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Phosphate Assessment in Chronic Kidney Disease Patients Study

NCT07368946
View directory record Official record
Conditions
Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease Mineral and Bone Disorder
Interventions
Dietary Phosphorus Intake
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 15, 2026, 1:55 PM EDT